Zenas BioPharma (NASDAQ:ZBIO) Issues Quarterly Earnings Results

Zenas BioPharma (NASDAQ:ZBIO) posted its quarterly earnings data on Monday. The company reported ($1.10) earnings per share (EPS) for the quarter, Zacks reports.

Zenas BioPharma Stock Performance

NASDAQ:ZBIO opened at $21.04 on Tuesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 5.61 and a current ratio of 5.61. Zenas BioPharma has a fifty-two week low of $7.34 and a fifty-two week high of $44.60. The firm has a market cap of $1.21 billion, a PE ratio of -2.69 and a beta of -0.54. The business has a 50 day moving average price of $23.38 and a 200-day moving average price of $27.43.

Insider Activity

In other news, Director Patricia L. Allen acquired 15,700 shares of the firm’s stock in a transaction on Thursday, February 12th. The shares were purchased at an average price of $24.85 per share, for a total transaction of $390,145.00. Following the completion of the transaction, the director owned 15,700 shares of the company’s stock, valued at $390,145. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Leon O. Moulder, Jr. acquired 57,000 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was purchased at an average price of $17.96 per share, for a total transaction of $1,023,720.00. Following the transaction, the chief executive officer directly owned 423,155 shares of the company’s stock, valued at approximately $7,599,863.80. This trade represents a 15.57% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 256,613 shares of company stock valued at $5,178,383 in the last three months. Corporate insiders own 22.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Quarry LP raised its position in Zenas BioPharma by 34.5% during the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after purchasing an additional 291 shares during the last quarter. Deutsche Bank AG raised its holdings in shares of Zenas BioPharma by 4.5% during the fourth quarter. Deutsche Bank AG now owns 12,781 shares of the company’s stock valued at $464,000 after acquiring an additional 554 shares in the last quarter. Two Sigma Investments LP raised its holdings in shares of Zenas BioPharma by 3.9% during the third quarter. Two Sigma Investments LP now owns 20,382 shares of the company’s stock valued at $452,000 after acquiring an additional 765 shares in the last quarter. Bank of America Corp DE lifted its stake in Zenas BioPharma by 5.8% in the third quarter. Bank of America Corp DE now owns 14,809 shares of the company’s stock worth $329,000 after acquiring an additional 818 shares during the period. Finally, Russell Investments Group Ltd. bought a new stake in Zenas BioPharma in the third quarter valued at $30,000.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Friday, March 27th. Citigroup lowered their price objective on shares of Zenas BioPharma from $43.00 to $41.00 and set a “buy” rating for the company in a report on Tuesday, March 17th. Guggenheim lifted their target price on shares of Zenas BioPharma from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, March 16th. Morgan Stanley boosted their price target on shares of Zenas BioPharma from $19.00 to $21.00 and gave the stock an “equal weight” rating in a research note on Tuesday, March 17th. Finally, Wedbush restated an “outperform” rating and set a $45.00 price target on shares of Zenas BioPharma in a research report on Monday, December 22nd. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $44.14.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.